TOP TEN perturbations for Q9P2Y5 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9P2Y5
Selected probe(set): 203241_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9P2Y5 (203241_at) across 5610 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-4.841793
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

zalypsis study 1 / untreated MM1S cell sample

Relative Expression (log2-ratio):-2.9490595
Number of Samples:2 / 2
Experimental zalypsis study 1
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated MM1S cell sample
MM1S multiple myeloma cells untreated.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.3695803
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 ?mol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):-2.2617788
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.2063665
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

actinomycin D study 1 / mannitol treated A549 cell sample

Relative Expression (log2-ratio):-2.18256
Number of Samples:3 / 3
Experimental actinomycin D study 1
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, actinomycin D (5 ug/mL final concentration) was added to the culture. ATC code:
Control mannitol treated A549 cell sample
A549 human lung cancer cells were seeded eights days prior to treatment of non-cycling plateau phase cultures with drug. At four hours prior to RNA isolation, mannitol (5% final concentration) was added to the culture.

A. fumigatus study 1 / uninfected immature dendritic cell sample

Relative Expression (log2-ratio):-2.0056229
Number of Samples:2 / 2
Experimental A. fumigatus study 1
5 x 106 immature dendritic cells were cultivated together with 5 x 106 A. fumigatus germ tubes for 6h until isolation of total RNA.
Control uninfected immature dendritic cell sample
5 x 106 immature dendritic cells were cultivated without fungi.

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-1.9780083
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-1.9685602
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

IgG; C3bi stimulation study 1 (late) / normal polymorphnuclear leukocyte sample

Relative Expression (log2-ratio):1.9215202
Number of Samples:10 / 11
Experimental IgG; C3bi stimulation study 1 (late)
Polymorphonuclear leukocytes (PMNs) from healthy donors, incubated with IgG- and C3bi-coated latex beads at 37?C in a CO2 incubator for 6h. ATC code:---
Control normal polymorphnuclear leukocyte sample
Polymorphonuclear leukocytes (PMNs) from healthy donors, incubated without IgG- and C3bi-coated latex beads at 37?C in a CO2 incubator for 6h.